- Trial phase
- Phase 1/1b
- Time to market
- Years away. ZL-1503 is in Phase 1/1b first-in-human testing. Even if development proceeds smoothly, regulatory filing would be at least 3-5 years out for a Phase 3 program in atopic dermatitis.
- Why 3/10
- ZL-1503 is a Phase 1 asset with no regulatory filing or pivotal trial readout scheduled. The nearest catalyst is a poster presentation of first-in-human healthy-volunteer data at ACAAI on November 13, 2026, which is an early scientific disclosure, not a binary decision. Zai Lab is a commercial-stage company with ~$441M in annual revenue and multiple pipeline programs; ZL-1503 is a small part of a diversified portfolio.
The next catalyst is a Phase 1/1b healthy-volunteer data poster at ACAAI on November 13, 2026 (Friday of next week). Watch for safety, PK, and biomarker signals. Clean data could modestly support the thesis; any safety signal or unremarkable PK would have little negative impact given the early stage. The much larger near-term binary for Zai Lab is the povetacicept PDUFA for IgAN on November 30, 2026.
Price Chart
Executive Summary
ZL-1503 is an early-stage (Phase 1/1b), internally discovered bispecific antibody from Zai Lab that targets both IL-13 (inflammation) and IL-31 (itching) pathways for moderate-to-severe atopic dermatitis. First-in-human healthy-volunteer data will be presented as a poster at the ACAAI conference on November 13, 2026. While the bispecific mechanism is novel and the atopic dermatitis market is large (over $3 billion), the drug is years from potential approval and faces a competitive field of already-approved biologics (dupilumab, lebrikizumab, nemolizumab, tralokinumab). Zai Lab is a commercial-stage company with roughly $441 million in trailing revenue from multiple marketed products, making ZL-1503 a small, early-stage piece of a much larger corporate story. The company's more imminent binary catalyst is the povetacicept PDUFA date for IgAN on November 30, 2026.
How It Works
ZL-1503 is a bispecific antibody engineered to simultaneously block two signaling proteins, IL-13 (which drives inflammation) and IL-31 (which drives itching). By targeting both pathways at once, the drug aims to break the "itch-scratch-inflammation cycle" that sustains atopic dermatitis (eczema). It also has an extended half-life, potentially allowing less frequent dosing than existing therapies.
Trial Status
The global Phase 1/1b first-in-human trial (NCT07235384) began dosing in December 2025 in healthy volunteers and moderate-to-severe atopic dermatitis patients across Australia, New Zealand, and other sites. A second Phase 1 PK study (NCT07658482) in healthy volunteers is also listed. First clinical data (from the healthy-volunteer single-ascending-dose portion) will be presented at ACAAI on November 13, 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1/1b healthy-volunteer data poster at ACAAI 2026 Annual Scientific Meeting on November 13, 2026 (Friday, 2:50 p.m. Mountain Time, Phoenix, AZ)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zai Lab Ltd 8-K ZLAB ·Originating report